PLK1 and liver cancer: Although a very recent study presented a preliminary finding that TP53-mutant Huh7 cells were more sensitive to PLK1 inhibitors than TP53-wild-type HepG2 cells, systematic analyses have not yet been conducted to characterize PLK1 as a specific target and PLK1 inhibitors as selective therapeutics of TP53-mutant liver cancer 68.